Cara Therapeutics, Inc. 4
4 · Cara Therapeutics, Inc. · Filed Feb 5, 2014
Insider Transaction Report
Form 4
Lewis Michael E
Chief Scientific Advisor
Transactions
- Conversion
Common Stock
2014-02-05+3,572→ 365,822 total - Conversion
Series D Preferred Stock
2014-02-05−8,931→ 0 total→ Common Stock (3,572 underlying) - Conversion
Common Stock
2014-02-05+40,000→ 362,250 total - Conversion
Series A Preferred Stock
2014-02-05−100,000→ 0 total→ Common Stock (40,000 underlying)
Footnotes (2)
- [F1]The Series A Preferred Stock held by the reporting person automatically converted on a 1-for-2.5 basis into shares of common stock upon the closing of the issuer's initial public offering.
- [F2]The Series D Preferred Stock held by the reporting person automatically converted on a 1-for-2.5 basis into shares of common stock upon the closing of the issuer's initial public offering.